Search

Your search keyword '"Emek Demir"' showing total 167 results

Search Constraints

Start Over You searched for: Author "Emek Demir" Remove constraint Author: "Emek Demir"
167 results on '"Emek Demir"'

Search Results

1. Multiplex imaging of localized prostate tumors reveals altered spatial organization of AR-positive cells in the microenvironment

2. Predicting transcription factor activity using prior biological information

3. Selective enrichment of plasma cell-free messenger RNA in cancer-associated extracellular vesicles

4. COVID19 Disease Map, a computational knowledge repository of virus–host interaction mechanisms

5. Systematic interrogation of mutation groupings reveals divergent downstream expression programs within key cancer genes

6. SBML Level 3: an extensible format for the exchange and reuse of biological models

7. Analyzing causal relationships in proteomic profiles using CausalPath

8. Author-sourced capture of pathway knowledge in computable form using Biofactoid

9. Cancer-associated mutations in DICER1 RNase IIIa and IIIb domains exert similar effects on miRNA biogenesis

10. Causal interactions from proteomic profiles: Molecular data meet pathway knowledge

11. Erratum To: COVID‐19 Disease Map, a computational knowledge repository of virus‐host interaction mechanisms

12. Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells

13. SBGNViz: A Tool for Visualization and Complexity Management of SBGN Process Description Maps.

14. Using biological pathway data with paxtools.

15. Automated network analysis identifies core pathways in glioblastoma.

16. The reactome pathway knowledgebase 2022.

18. Pathway Commons 2019 Update: integration, analysis and exploration of pathway data.

19. Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors

22. Computational modeling of methylation impact of AML drivers reveals new pathways and refines AML risk-stratification

23. Supplementary Table 5 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

24. Supplementary Fig. 5 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

25. Supplementary Table 8 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

26. Supplementary Table 7 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

27. Supplementary Materials and Methods from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

28. Supplementary Table 15 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

29. Supplementary Fig. 6 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

30. Supplementary Fig. 11 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

31. Supplementary Fig. 8 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

32. Supplementary Table 9 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

33. Supplementary Fig. 2 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

34. Supplementary Table 6 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

35. Supplementary Fig. 3 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

36. Supplementary Fig. 9 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

37. Supplementary Fig. 4 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

38. Data from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

39. Supplementary Table 3 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

40. Supplementary Table 2 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

41. Supplementary Table 4 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

42. Predicting transcription factor activity using prior biological information

45. Selective enrichment of plasma cell-free messenger RNA in cancer-associated extracellular vesicles

48. An expanded universe of cancer targets

49. Software support for SBGN maps: SBGN-ML and LibSBGN.

Catalog

Books, media, physical & digital resources